Kala Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Earnings Release (Form 10-Q) | 13 Nov 2026 |
| FY 2026 Annual Earnings Release (Form 10-K) | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Researgency AI Platform Enterprise Deployments Quarterly1.0Target: Scale to multiple biotech and pharmaceutical enterprise clients
Cash and Cash Equivalents (USD) Quarterly1.8MTarget: Maintain sufficient runway to fund operations into Q2 2027
Short-term Investment Loan Balance (USD) Quarterly7MTarget: Manage debt obligations under the Minglemint 8.0% secured promissory note
Watch Items
- Commercialization and monetization of legacy biologics assets (KPI-012 and KPI-014)Trigger: Execution of licensing, collaboration, or asset sale agreementsAction: Re-evaluate valuation multiples and adjust long-term growth projections based on non-dilutive cash inflows.
- Enterprise adoption and pilot-to-paid conversion of the Researgency AI platformTrigger: First commercial contract signed with a paying biotech/pharma customerAction: Update revenue forecasts for FY 2026 and FY 2027 to reflect software-as-a-service (SaaS) recurring revenue.
- Nasdaq continued listing complianceTrigger: Stock price falling below $1.00 minimum bid price requirement post-reverse splitAction: Monitor market capitalization and evaluate potential capital restructuring or additional reverse split actions.
Research as of 20 Jun 2026